Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 Europe company AstraZeneca, showed significant improvements in overall survival in people with germline BRCA-mutated high-risk early breast cancer (gBRCAm), HER2 negative, 2024 clinical trial data suggests.
Jaime Grajales Benjumea—Getty Images
#MerckAstraZeneca #breast #cancer #drug #Lynparza #improves #longterm #survival #clinical #trial #shows